OncoMatch/Clinical Trials/NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Is NCT05652686 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Peluntamig (PT217) and Carboplatin + Etoposide for small cell lung cancer (sclc).
Treatment: Peluntamig (PT217) · Carboplatin + Etoposide · Paclitaxel. · Atezolizumab — This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Pancreatic Cancer
Biomarker criteria
Required: DLL3 overexpression
tumor tissue...to be assessed for DLL3 expression and other biomarkers
Disease stage
Metastatic disease required
Grade: well differentiated grade 3 (Ki-67 ≥ 55%) allowed if DLL3 positive (Ki-67)
histologically or cytologically confirmed unresectable advanced or metastatic... Patients with well differentiated grade 3 neuroendocrine tumors (Ki-67 ≥ 55%) may be considered if their tumors are DLL3 positive.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — SCLC
at least one line of platinum-based chemotherapy with or without immune checkpoint inhibitor for SCLC patients
Lab requirements
Blood counts
adequate organ function confirmed at screening and within 72 hours of initiating C1D1
Kidney function
adequate organ function confirmed at screening and within 72 hours of initiating C1D1
Liver function
adequate organ function confirmed at screening and within 72 hours of initiating C1D1
Cardiac function
impaired cardiac function or significant diseases excluded; for Part D only, significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina excluded
Adequate organ function confirmed at screening and within 72 hours of initiating C1D1 of Peluntamig (PT217) treatment. Impaired cardiac function or significant diseases. For Part D only, significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) · Duarte, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins · Baltimore, Maryland
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05652686 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy.
Does this trial require DLL3?
Yes, DLL3 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify